Neoplasm Metastasis (Metastasis)

03/01/1995 - "When 5-fluorouracil was injected at a dose of 15 mg/kg/day every other day after the inoculation of tumour cells a highly significant reduction in the incidence of metastases was seen (compared with the controls). "
04/01/2000 - "This randomized study revealed that short term HAI of 5-FU after curative resection of colorectal hepatic metastases is effective in preventing the recurrence of disease without any serious complications."
10/01/2003 - "Arterial infusion therapy with 5-fluorouracil (5-FU) was given at 1,500 mg every 2 weeks up to a total dose of 37.5 g, resulting in complete remission (CR) of the liver metastases. "
09/01/1996 - "A total dose of 1,150 mg of MTX and 6,250 mg of 5-FU caused a marked decrease in the volume of liver metastases and the effect remained for 8 months (partial response). "
04/12/1996 - "Of 120 patients receiving a combination of rIL-2, rIFN-alpha 2 and 5-FU, 13 patients achieved a complete and 34 a partial remission (lung, liver, local relapse, bone, adrenal, pleural, and thyroid metastases; overall response 39%). "

09/01/1997 - "[A case of multiple colonic liver metastases treated successfully with percutaneous isolated liver chemoperfusion using cisplatin]."
04/01/2013 - "This retrospective study was aimed at assessing the oncologic efficacy of weekly cisplatin chemoradiotherapy for the control of nodal metastasis. "
01/01/1997 - "The other patient had evidence of pulmonary metastases: following cisplatin therapy, she underwent clinical remission. "
05/01/2014 - "In this study, we investigated the effects of cisplatin (CDDP) on metastasis and invasion suppression of ovarian CICs by targeting the CXC chemokine receptor-4 (CXCR4) signaling pathway in vitro and in vivo. "
01/01/2013 - "This study shows that transcatheter arterial chemoembolization with cisplatin powder at a dose of 80 mg/m(2) mixed with DSM is well tolerated and can produce a high response rate with a long survival time for patients with unresectable colorectal liver metastases after failure of FOLFOX."

10/01/2008 - "CT showed a complete response on lung metastases and lymph node metastases and marked decrease of liver metastases after the first course of IL-2. "
07/01/1999 - "The median disease-free interval in the brain after resection of a single metastasis was 21, 7, and 3 months for patients achieving a complete response, partial response, and no response (CR, PR, and NR) to IL-2 therapy, respectively. "
01/01/1995 - "Of 33 patients, one achieved a complete remission (response duration, 24 months) and two patients presented with partial remissions (median response duration, 7 months) of pulmonary metastases upon rIFN-alpha/5-FU after failing SC recombinant interleukin-2 (rIL-2) and rIFN-alpha. "
12/01/1986 - "A single patient with pulmonary and hepatic metastases showed marked decrease in these lesions with intraperitoneal IL-2 treatment. "
04/01/2004 - "Inhalation of IL-2 for the treatment of pulmonary metastases in RCC is feasible, tolerable and beneficial in controlling progressive disease for considerable periods of time. "

06/01/2008 - "Bisphosphonates are the most effective agent for treating and (or) preventing complications of bone metastasis, reducing the incidence of skeletal-related events, and improving quality of life in patients with bone metastasis."
01/01/2008 - "Bisphosphonates, which inhibit excessive osteoclast activity caused by ADT and bone metastases, have proven to be safe and effective in preventing skeletal complications and presently are the standard of care in patients with metastatic disease. "
12/01/2007 - "Bisphosphonates have proven efficacy in reducing and delaying skeletal-related events in patients with bone metastases, and play a key role in preserving patient functional independence and quality of life. "
05/01/2004 - "Bisphosphonates are potent inhibitors of osteoclast activity that have demonstrated efficacy in the treatment of bone metastases. "
01/01/2004 - "There has been a marked improvement in the time between the diagnosis of bone metastases and the commencement of bisphosphonates from a median of 155 days in 1998 to 24 days in 2001. "

01/01/2004 - "Zoledronic acid was significantly more effective than placebo on most efficacy measures in patients with bone metastases secondary to other solid tumours (e.g. "
12/01/2002 - "Zoledronic acid is the first and only bisphosphonate to be proved effective in patients with all types of bone lesions, from osteolytic to osteoblastic, and therefore represents an important therapeutic advancement in the treatment of bone metastases."
01/01/2005 - "Zoledronic acid(ZOMETA): a significant improvement in the bone metastases."
01/01/2015 - "BS is effective for assessing the response of bone metastasis to therapy in patients during zoledronic acid treatment."
04/01/2012 - "Zoledronic acid, although underutilized in genitourinary malignancies, has long been the mainstay of treatment in patients with bone metastases, and can also help preserve bone during anticancer therapy. "

07/01/1996 - "We present the first clinical report of a serologic remission with high-dose paclitaxel (250 mg/m2 i.v. infusion over 24 h every 3 weeks) of a highly refractory GTD in a patient who developed brain metastasis after multiple combined chemotherapeutic regimens. "
07/01/2015 - "Strikingly, a significant reduction of lung metastasis in mice was observed in the AC1MMYR2 plus taxol treatment. "
09/01/2005 - "These results indicate that intraperitoneal paclitaxel is effective against peritoneal metastasis in early phase."
12/01/1994 - "Paclitaxel was effective against the patient's abdominal and pelvic disease but was not protective against central nervous system metastasis."
01/01/2015 - "Our study thus demonstrates IRAK1 as a promising therapeutic target for TNBC metastasis and paclitaxel resistance. "

10/01/2010 - "NK012 eradicated the liver metastases and produced a significant longer survival rate than CPT-11 (P = 0.0006). "
11/01/2007 - "HAI (WHF: 1000 mg/m2) plus CPT-11 (100 mg/m2) was effective, and liver metastases showed a significant reduction (PR) on abdominal CT. "
03/01/2003 - "Combination therapy of FR-WBH + CPT-11 resulted in a significantly greater inhibition of axillary lymph node metastasis volume compared to both control and CPT-11 alone (p < 0.02) at day 16. "
11/01/2007 - "HAI plus CPT-11 was effective for a patient of the poor performance status with unresectable liver metastasis."
04/01/2015 - "To compare the feasibility, safety, and efficacy with small and large irinotecan drug-eluting beads (DEBIRI) for treating hepatic colorectal metastases. "

11/01/2007 - "In some prospective studies, neoadjuvant hormones prior to external beam radiation therapy have been shown to significantly improve disease-free, disease-specific and overall survival as well as to reduce local recurrence or metastases. "
08/01/2014 - "In addition to hormone receptor and HER2 status, multiple other factors are predictive of relatively poorer clinical outcomes, including visceral metastasis, short disease-free interval between the end of treatment for early-stage disease and diagnosis of MBC, and higher number of metastatic sites. "
07/25/1991 - "In conclusion, age, 131I whole body scanning and serum thyroid hormone concentrations are considered to be useful in predicting the efficacy of 131I treatment for distant metastases, especially in the lung."
08/01/2015 - "The poor prognostic factors were disease-free interval (DFI) (<3 years) with HR =1.70 (95% CI: 1.37-2.10), resection of metastases (incomplete) with HR =2.06 (95% CI: 1.63-2.62), No. of pulmonary metastases (>1) with HR =1.31 (95% CI: 1.13-1.50) and the hormone receptor status of metastases (negative) with HR =2.30 (95% CI: 1.43-3.70). "
09/01/2014 - "Radiological features and immunohistochemistry especially for steroid hormone receptors (ER/PR) and expression of gross cystic disease fluid protein (GCDFP) and presence of other immunohistochemistry protein factors in breast metastasis which are specific to primary site may be helpful in differentiating these two conditions. "

03/01/2015 - "Interestingly, when administered together with a suboptimal, poorly effective, dose of doxorubicin (DXR), cyclicCHAD improved survival and reduced visceral metastases volume to a level similar to that of the optimal dose of DXR alone. "
01/01/1986 - "An asynchronous regional metastasis was successfully eradicated with adriamycin. "
12/01/1993 - "At an average follow-up of 54 months (36-76), 109 patients (66%) were continuously disease-free, 2 died from doxorubicin cardiotoxicity, and 52 experienced metastases and 3 had local recurrence. "
10/01/2015 - "These results suggest that the treatment of hMSCs with a sub-toxic dose of doxorubicin can overcome TRAIL resistance and be a potential novel therapy for TNBC metastasis treatment."
07/01/2015 - "Actively targeted delivery of doxorubicin to bone metastases by a pH-sensitive conjugation."

12/01/1995 - "Docetaxel also was found to be highly effective in patients with a poor prognosis, having metastases in three or more organs (53%), and/or visceral sites of disease (47%). "
04/01/2005 - "In September 2000, she was treated with docetaxel for multiple lung metastases, and the lesions were diagnosed as in complete remission. "
04/01/2004 - "A weekly administration method of docetaxel was therefore selected, resulting in complete remission of the pulmonary metastasis and a partial response of the local recurrence. "
04/01/1998 - "We, therefore, treated her six times with docetaxel 80 mg, which resulted in partial response of the liver metastasis and brought about a marked decrease in serum CA15-3 levels. "
09/01/1998 - "Docetaxel is not recommended for patients with liver metastases or impaired liver function because clearance of the drug is impaired. "

01/01/2012 - "The present study suggests that radioembolization shows promise as an effective and safe treatment for patients with chemotherapy-refractory hepatic metastases and improves overall survival in a select population of patients in a salvage setting compared with best supportive care alone."
05/01/1998 - "Nevertheless, this technique seems to be able to yield the best results in: fetal malformations; calculating the volumes of normal and diseased organs; the follow-up of masses treated with irradiation/chemotherapy or with alcohol or chemoembolization; the spatial reconstruction of extensive lesions; the detection of small lesions (metastases); the study of some complex functions such as cardiac valve dynamics. "
05/01/2014 - "To retrospectively evaluate findings of chemotherapy-induced focal hepatopathy (CIFH) on gadoxetic acid-enhanced magnetic resonance (MR) and diffusion-weighted (DW) images and to determine imaging features that are most helpful in differentiating CIFH from metastasis. "
05/01/2012 - "Selected arterial infusion chemotherapy with targeted drugs is one of the most effective and safe treatment to NSCLC with multiple brain metastases. "
06/01/2010 - "ILuP with high-dose chemotherapy has proven to be highly effective in the experimental models of pulmonary metastases with a superior survival advantage compared with systemic treatment. "

01/01/2012 - "Little is known about what the best treatment is for patients returning with painful bone metastases after their first radiotherapy. "
01/01/2003 - "Surgery and whole brain radiotherapy for the treatment of single brain metastasis in patients with stable extracranial disease is at the present time the best treatment option for this particular group. "
02/01/1997 - "Radiotherapy is effective for the management of most uveal metastases, and standard external beam radiotherapy is generally administered during a 3-to 4-week period. "
05/01/1993 - "For a long time, radiotherapy was considered as the best treatment for spinal metastases. "
04/01/1986 - "Radiotherapy seems to be the most effective treatment for symptomatic osseous metastases."

01/01/2000 - "The evaluation of treatment outcome proved that bilateral lymphadenectomy, as suggested by Bocca, is highly effective in management of lymph node metastases."
01/01/1992 - "The best treatment results are by patients treated with radical vulvectomy and regional lymph node dissection, without histological founded metastases in the extirpated lymph nodes--69.24% five years survival. "
03/01/2010 - "Knowledge of the pattern and incidence of lymph node metastasis may help to define the optimal extent of lymph node dissection. "
06/01/2006 - "Radio-guided surgery (RGS) leads to complete clearance of persistent lymph node metastases by limited recurrent neck surgery, resection of metastases not seen by conventional imaging and control of complete mediastinal lymph node dissection. "
12/03/2008 - "Pelvic systematic lymphadenectomy improved surgical staging as statistically significantly more patients with lymph node metastases were found in the lymphadenectomy arm than in the no-lymphadenectomy arm (13.3% vs 3.2%, difference = 10.1%, 95% confidence interval [CI] = 5.3% to 14.9%, P < .001). "

11/01/2014 - "Adjuvant chemotherapy was highly effective against local relapses [HR = 0.73; 95% confidence interval (CI) 0.60-0.90; P = 0.003] and nonbrain metastases (HR = 0.79; 95% CI 0.66-0.94; P = 0.008) but not against brain metastases (HR = 1.1; 95% CI 0.82-1.4; P = 0.61). "
11/01/2011 - "Adjuvant chemotherapy with S-1 resulted in complete remission of lung metastases. "
01/01/2004 - "Neoadjuvant or adjuvant chemotherapy did not provide a significant survival advantage, although adjuvant chemotherapy improved the 5-year overall survival in patients with pathologically proven lymph node metastasis. "
03/01/2015 - "Aggressive cytoreductive surgery with multiorgan resection, peritonectomy, HIPEC and adjuvant chemotherapy which was proved to be a feasible option in some patients, with synchronous liver resection (LR) proved to be feasible and beneficial for patients with three or fewer liver metastases. "
05/01/2014 - "Adjuvant chemotherapy significantly improved RFS (P = 0.002) and CSS (P = 0.001) in patients with lymph node metastasis. "

10/10/2008 - "The rapid expansion in the use of improved combination chemotherapy regimens plus or minus biologics, to render initially unresectable metastases resectable has increased the percentage of patients eligible for potentially curative surgery. "
05/01/2006 - "Polychemotherapy rarely leads to long-lasting complete remission in patients with distant metastases. "
01/01/1995 - "The use of high-dose therapy to selected patients with metastases/recurrence responding to conventional doses of polychemotherapy may lead to an improved survival tail. "
12/01/2013 - "Combination chemotherapy may prove effective for patients with HCC accompanied by LN metastases that show features of EMT. "
08/01/1975 - " In addition, evaluation for a disease free interval greater or less than two years, menopausal status and visceral or nonvisceral metastasis did not allow identification of groups predicting responsiveness to combination chemotherapy."